Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
Moreno-Romero
Juan A
JA
Department of Dermatology, Hospital Clínic, University of Barcelona, Barcelona, Spain. 26305jmm@comb.es
Fernández-Avilés
Francesc
F
Carreras
Enric
E
Rovira
Montserrat
M
Martínez
Carmen
C
Mascaró
José M
JM
D000293:Adolescent; D001549:Benzamides; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000601:surgery*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012594:Scleroderma, Localized / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate